重组人白介素11治疗恶性血液病化疗相关性血小板减少46例观察

摘要

目的：观察重组人白介素-11（ rh-IL11）治疗恶性血液病化疗相关性血小板减少的疗效及安全性。方法：选取我院2003年2月至2013年2月间收治的92例恶性血液病住院患者，随机分为治疗组和对照组各46例。2组均行常规化疗。治疗组在化疗后加用rh-IL11。观察2组疗效及不良反应。结果：治疗组化疗后PLT持续低下时间、PLT输注率均优于对照组（ P＜0.05）。2组均无严重不良反应发生。结论：rh-IL11可降低化疗所致血小板下降的幅度，缩短血小板持续低下的时间，且副作用少，可作为治疗恶性血液病化疗相关性血小板减少的安全有效药物。%Objective:To observe the effects of recombinant human interleukin -11(rh-IL11)in the treatment of patients with Thrombocytopenia after Chemotherapy of Hematological Malignancies. Methods:92 patients with malignant hematologic disease in our hospital from 2003 February to 2013 February were randomly divided into treatment group and control group with 46 cases in each. The two groups were treated with conventional chemotherapy. The patients in treatment group were added with rh -IL11. Observed the curative effect and adverse reaction. Results:The continuous low PLT time and PLT infusion rate in the treatment group after chemotherapy were lower than that of in the control group( P <0. 05 ). There were no serious adverse reactions in the two groups. Conclusion:rh-IL11 can reduce low PLT time and PLT infusion rate,and have less side effects,and can be used as an effective and safe drug in the treatment of patients with Thrombocytopenia after Chemotherapy of Hematological Malignancies.